ProCyte Corp. stock jumped $2 on Wednesday after thecompany said it has received notice of allowance that a U.S.patent will issue covering the composition and use of itspeptide-metal compounds that stimulate hair growth inanimals.
The Kirkland, Wash., company is conducting European trials ofits hair growth enhancer, Tricomin. Preliminary results fromthe Phase II study, which began in January 1991 and isscheduled to end in the first quarter, showed that more than80 percent of men have had significant normal hair growth asearly as two months after the start of twice-daily application.
The Upjohn Co.'s Rogaine minoxidil is the only productcurrently licensed for use to stimulate hair growth.
The stock (NASDAQ:PRCY) closed at $14.
(c) 1997 American Health Consultants. All rights reserved.